In January 2014 Sequoia genetics (Saint-Petersburg, Russia) announced that the development of diagnostic solution intended for diagnostics of inherited diseases in newborns based on the next-generation sequencing (NGS) technology has been completed. The solution named VariFind Neonatal assay based on Ion PGM (Life Technologies, US) sequencing platform and consists of reagents kits, protocols and specialized software.

On October, 7-11, Alkor Bio Group of Companies has been assessed for compliance with the International standards ISO 9001 and ISO 13485.

Sequoia genetics Co. Ltd. announced the beginning of clinical trials of diagnostic system for severe hereditary diseases detection in newborns and carrier state in couples planning a family. The developed molecular genetic solution is based on next generation sequencing (NGS) technology and consists of reagents kits and specialized software. Since the solution is designed for the mutation detection in clinics a special attention has been given to the issue of traceability and unambiguity of sequencing results in order to ensure the accuracy and reproducibility of the assay. To provide extensive clinical trials Sequoia genetics established partnership with several European laboratories: Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP, Portugal), StabVida company (Portugal) and the Center for Genome Research at the University of Liverpool (UK).